Pharmacological treatments for fragile X syndrome based on synaptic dysfunction.

CONCLUSION: In this concise review, we summarize and analyze the main hypotheses proposed to explain synaptic dysregulation in FXS, by reviewing the scientific evidence that led to pharmaceutical clinical trials and their outcome. PMID: 31682210 [PubMed - as supplied by publisher]
Source: Epilepsy Curr - Category: Neurology Authors: Tags: Curr Pharm Des Source Type: research